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"
Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: evidence from the 49"
Building Blocks trial 50"
 51"
Abstract  52"
 53"
Rational, aims and objectives: The Family Nurse Partnership (FNP) is a licensed intensive home visiting 54"
intervention developed in the USA. It has been provided in England by the Department of Health (DH) since 55"
2006. The Building Blocks (BB) trial assessed the effectiveness and cost-effectiveness of FNP in England.   56"
 57"
Methods: We performed a cost-utility analysis (NHS perspective) alongside the BB trial (over 2.5 years). The 58"
analysis was conducted in accordance with NICE (National Institute for Health and Clinical Excellence) 59"
reference case standards. Health-related quality of life was elicited from mothers using the EQ-5D-3L. Resource 60"
use data were collected from self-reported questionnaires, Hospital Episode Statistics (HES), general 61"
practitioner records and the central DH FNP database. Costs and quality-adjusted life years (QALYs) were 62"
discounted at 3.5%. The base case analysis used an intention to treat approach on the imputed dataset using 63"
multiple imputation (MI).  64"
 65"
Results: The FNP intervention costs on average £1812 more per participant compared to usual care (95% CI -66"
£2700; £5744). Incremental adjusted mean QALYs are marginally higher for FNP (mean difference 0.0036, 67"
95% CI -0.017; 0.025). The probability of FNP being cost-effective is less than 20% given the current NICE 68"
willingness to pay threshold of £20 000 per additional QALY. The results were robust to sensitivity analyses.  69"
 70"
Conclusion: Given the absence of significant benefits of FNP in terms of the primary outcomes of the trial and 71"
only marginal maternal QALY gains, FNP does not represent a cost-effective intervention when compared with 72"
existing services already offered to young pregnant women. 73"
 74"
 75"
 76"
 77"
 78"
 79"
3"
"
INTRODUCTION 80"
 81"
The Family Nurse Partnership (FNP) programme is an intensive preventive home visiting service with positive 82"
results compared to usual services for mothers and babies both in the USA and the Netherlands [1-4]. It was 83"
introduced for first time young mothers into NHS England by the Department of Health in 2006 [5-7]. In 84"
October 2015 the FNP was transferred from NHS England to Local Authorities (LAs) and it is provided in 85"
approximately 125 different LAs in England. The FNP programme was introduced to be an integral part of the 86"
progressive universalism approach recommended in The Healthy Child Programme (HCP). The HCP is 87"
delivered by the Family Nurse rather than by health visitors for women who enrol onto the programme.  88"
Given the lack of evidence on the benefits of the FNP programme in England, the Building Blocks (BB) trial 89"
was commissioned to evaluate the effectiveness and cost-effectiveness of the FNP intervention when delivered 90"
in a comprehensive publicly funded health care setting. The BB protocol has been published 11 and all 91"
amendments were reviewed and approved by the Wales NHS Research Ethics Committee (09/MRE09/08). The 92"
details of the trial design, outcomes and clinical effectiveness are reported elsewhere 12, 13. The results from 93"
the effectiveness analysis showed no statistically or clinically significant difference associated with FNP for any 94"
of the four  primary outcomes: smoking cessation (adjusted OR 0·90, 97·5% CI 0·64–1·2), birth weight 95"
(adjusted mean difference 20·75 g, 97·5% CI –47·73 to 89·23),  second pregnancies within two years (AOR 96"
1·01, 0·77–1·33), or child A&E attendances and admissions to hospital (AOR 1·32, 97·5% CI 0·99–1·76, 97"
p=0.03).  98"
This paper reports on the cost-effectiveness analysis conducted alongside the Building Blocks (BB) trial. This 99"
economic analysis also seeks to better understand a key example of an intervention that is routinely provided 100"
without clear evidence on whether it represents good value for money for the health system compared to 101"
comprehensive services, which in turn may help to guide disinvestment decisions that are unavoidable given the 102"
financial constraints within a publicly funded health care system. 103"
 104"
METHODS 105"
 106"
Overview 107"
Individual patient data from the BB trial were used to perform a cost-utility analysis measuring health-related 108"
quality of life (HRQoL) in terms of quality-adjusted life years (QALYs). The analysis was from the NHS and 109"
4"
"
personal social services (PSS) perspective and expressed in UK pounds sterling (2013 GBP). Costs and QALYs 110"
were discounted at a rate of 3.5% [8]. We used a regression approach on an intention-to-treat (ITT) basis. The 111"
base case analysis was conducted on the dataset generated by multiple imputation by chained equations [9]. 112"
Sensitivity analysis included complete case (CC) analysis to test the impact of excluding participants with 113"
missing data on the final results. All analyses and modelling were conducted in Stata 13.1 (StataCorp 2011, TX, 114"
USA). 115"
The BB trial was a pragmatic, non-blinded, parallel-group, randomised controlled trial (RCT) which recruited 116"
within a community midwifery setting at 18 partnerships between LAs and primary and secondary care 117"
organisations in England. The trial compared two arms; usual care (through primary-care public health and 118"
social care services) plus FNP (FNP group) to usually provided health and social care alone (usual care group). 119"
These groups were followed from early pregnancy (as soon as possible from the end of the first trimester) until 120"
two years following childbirth. The trial recruited 1645 teenagers expecting their first baby, at less than 25 121"
weeks gestation, between 16th June 2009 and 28th July 2010. The economic analysis is based on the 1618 122"
participants that were assessed as eligible and did not withdraw consent for their data to be used. Mandatory 123"
withdrawals (e.g. miscarriage, termination for fetal anomaly) were not included in the primary analysis 124"
(FNP=26; usual care=24). Hence a total of 1568 (FNP=782; usual care=786) women were included in the base 125"
case analysis.    126"
 127"
Health outcomes and quality-adjusted life-years 128"
The primary outcome measure was QALYs, based on the EQ-5D-3LTM (EuroQoL Group Rotterdam, The 129"
Netherlands) reported by the women. The EQ-5D-3L has been used before in the UK setting within the context 130"
of a pregnant population, for example in the economic evaluation conducted alongside the Early Labour Support 131"
and Assessment (ELSA) trial [10]. The EQ-5D-3L health states were valued using a UK-based social tariff [11]. 132"
QALYs were calculated using the area under the curve method (AUC) [12] and were adjusted for baseline 133"
utility[13].  134"
 135"
 136"
 137"
5"
"
Resource use and costs 138"
Costs and health outcome data were collected via self-reported questionnaires at various time-points throughout 139"
the trial: baseline, late pregnancy (34-36 weeks gestation), and 6, 12, 18 and 24 months postpartum. Baseline 140"
and 24 month data were collected by face-to-face interview by a locally based researcher.  Follow-up self-141"
reported data were collected via telephone by qualified telephone interviewers for the remainder of the time-142"
points.  Data related to the use of hospital services were obtained from maternity notes, the Health and Social 143"
Care Information Centre (HSCIC, Hospital Episode Statistics (HES)); and general practitioner (GP) visits were 144"
obtained from GP records. The cost of the FNP intervention was based on the centralised FNP Information 145"
System (IS) database run by Connecting for Health in Exeter (e.g. number of nurse visits, duration of visit, 146"
number of telephone encounters). The unit costs used to estimate the total cost per participant in the trial are 147"
presented in Table 1, sourced from the Personal Social Services Research Unit [14] and NHS reference costs 148"
[15].  149"
Table 1 150"
 151"
 152"
Handling missing data 153"
Complete case assessment excludes all participants with any missing or incomplete data. Excluding patients 154"
with missing data leads to  loss of power and biasing of the results due to a reduced sample size [16]. The 155"
method we used to handle missing data was informed by the BB data. Incomplete data on costs and QALYs 156"
were imputed using multiple imputation (MI) with chained equations and predictive mean matching; which 157"
assumes that data are missing at random (MAR) [17-19]. The same set of covariates as in the clinical 158"
effectiveness analysis was selected with stepwise regressions (e.g. site, smoking status, language and gestation). 159"
Rubin´s rules were used to combine point and variance estimates across imputed datasets, allowing the 160"
estimation of difference in costs and QALYs between both groups [20].  161"
 162"
Base-case analysis 163"
The base-case analysis was conducted on the multiple imputed dataset, and followed an intention-to-treat (ITT) 164"
approach. For the base-case analysis total costs constituted the cost of the FNP programme (nurse time used for 165"
6"
"
home based visits from the FNP nurse); GP and nurse visits (recorded in GP records), post-natal midwife and 166"
health visitor visits (self-reported by mothers); and hospital activity (HES records for inpatient admission, 167"
outpatient visits and A&E services).  168"
The cost-effectiveness of the FNP programme was evaluated by comparing the mean differences in costs and 169"
effects in the two groups, using conventional rules and estimating the incremental cost-effectiveness ratio 170"
(ICER) as appropriate [21]. The mean differences in costs and QALYs were estimated using seemingly 171"
unrelated regression (SUR) [22], and their 95% confidence intervals (CI) estimated using bias corrected and 172"
accelerated (BCA) bootstrap methods. Non parametric bootstrapping [23] was used to transform the uncertainty 173"
around the trial estimates into the probability that the FNP intervention is cost-effective for thresholds used by 174"
the National Institute for Health and Care Excellence (NICE) of £20 000 and £30 000 per QALY gained [8], 175"
with cost-effectiveness acceptability curves (CEACs) used.  176"
 177"
Sensitivity analyses 178"
Sensitivity analyses in the base case were conducted to test the robustness of the results using five scenarios: 179"
complete case (CC) analysis according to ITT; MI removing midwife visits reported by mothers allocated to 180"
FNP (i.e. to avoid double counting in case those visits were already included in the FNP IS dataset); MI 181"
including the limited data available for mothers that withdrew due to mandatory withdrawals (i.e if FNP were to 182"
be implemented, costs related to mandatory withdrawals would be covered by the NHS); MI using self-report 183"
data (i.e including resource use exclusively related to mothers, hence excluding resource use related to babies); 184"
and MI halving the cost for the FNP intervention.   185"
 186"
RESULTS  187"
 188"
The results from the effectiveness analysis showed no statistically or clinically significant difference associated 189"
with FNP for any of the four  primary outcomes: smoking cessation (adjusted OR 0·90, 97·5% CI 0·64–1·2), 190"
birth weight (adjusted mean difference 20·75 g, 97·5% CI –47·73 to 89·23),  second pregnancies within two 191"
years (AOR 1·01, 0·77–1·33), or child A&E attendances and admissions to hospital (AOR 1·32, 97·5% CI 192"
0·99–1·76, p=0.03).  193"
7"
"
Health outcomes and quality-adjusted life-years 194"
Table 2 presents the proportion of participants with complete EQ-5D data. A small number of trial participants 195"
(n=10) allocated to the control arm were erroneously enrolled into FNP. Following the ITT principle they were 196"
analysed in their allocated arm regardless. Data were considered missing or incomplete when women did not 197"
complete the EQ-5D or provided a partially completed questionnaire. Two points would support the MAR 198"
assumption used as the basis for the base-case analysis: (i) the missing data followed an intermittent pattern (e.g. 199"
in both groups, more women were observed at 12 months than at six months, and the same pattern is observed at 200"
18 and 24 months)  hence complete case assessment would be, as a minimum, inefficient because it would 201"
discard observed data from individuals with some missing outcomes; and (ii) the BB data showed that 202"
participants with lower EQ-5D at baseline were more likely to have missing QALY data, which in turn suggests 203"
that the data are unlikely to be MCAR.  204"
Participants in the FNP group started from a lower baseline HRQoL was a mean (SD) of 0.90 (0.005) (FNP) 205"
versus 0.91 (0.005) (usual care). The EQ-5D-3L scores did not differ significantly between groups at each 206"
follow-up (Table 3). The difference in mean EQ-5D-3L scores at 2 years (FNP – usual care) when controlling 207"
for baseline utility (for available cases: 320 FNP versus 265 usual care) was -0.008 (95% CI -0.023 to 0.008).  208"
Table 2  209"
 210"
Despite any difference seen in the EQ-5D-3L across the groups, this translates to very little difference in utilities 211"
(Figure I) and QALYs between the FNP and usual care groups.  212"
Figure 1 213"
 214"
Resource use and costs 215"
There were no clear differences in resource use across the two groups (Table 3), though A&E attendances for 216"
mothers and babies were somewhat higher in the FNP group. Babies in the usual care group had on average 217"
longer inpatient length of stay in hospital than those babies whose mothers were randomised to the FNP 218"
intervention.  219"
Table 3 220"
8"
"
 221"
Cost differences were very small across groups (Table 4). Costs associated with the delivery of the FNP 222"
intervention and the inpatient stays in hospital for babies were the major cost drivers for the cost-effectiveness. 223"
Using the principle of ITT and assigning a cost of £0.00 to women who did not receive the intervention, the 224"
average cost of nurse time for FNP visits was £3845 (SD £77), and £33 (SD £2) for FNP phone calls; however, 225"
considering only the 719 women who received the intervention, the average cost of nurse time was £4,270 (SD 226"
£1,855) per woman. If we assume that on average women were recruited at 18 weeks gestation then, the annual 227"
cost of nurse time for the FNP home visits is £1,762 per women. 228"
Table 4 229"
 230"
Cost-effectiveness analysis 231"
The incremental analysis (Table 5), when adjusting for all covariates (baseline utility, site, smoking status, 232"
language and gestation), showed the FNP intervention costs on average £1811 more per participant when 233"
compared with usual care (95% CI -£2814; £5547). Incremental mean QALYs when adjusted for baseline utility 234"
are marginally higher for FNP (mean difference 0.0036, 95% CI -0.017; 0.025). This difference is even lower 235"
when adjusted for the remaining covariates (mean difference 0.0030, 95% CI -0.017; 0.027). The Net Monetary 236"
Benefit associated with the FNP intervention is negative (-£1750.57), indicating that the resources displaced 237"
would be greater than the benefit gained with the delivery of the FNP intervention. The probability of the FNP 238"
intervention being cost-effective was less than 20% given the NICE currently accepted threshold of £20 000 to 239"
£30 000 per additional QALY (Figure 2).  240"
Table 5 241"
 242"
Figure 2 243"
 244"
The sensitivity analyses (Table 5) showed that the conclusions from the base case analysis were robust to all 245"
scenarios, FNP remained a non-cost-effective intervention, with the ICERs much higher than the thresholds that 246"
NICE normally consider for reimbursement decisions. Because it was felt that the cost of the intervention is the 247"
main cost driver for the analysis, the cost of the FNP intervention was halved to assess the effect on the cost-248"
9"
"
effectiveness conclusions. The mean difference in costs per participant is reduced to £360 (95% CI £-3680 to 249"
£4352); the gain in QALYs is still very marginal at 0.0047 (95% CI -0.013; 0.022). The results continue to be 250"
uncertain and the probability of FNP being cost-effective less than 50%. The complete case analysis shows that 251"
the FNP intervention cost, on average, £4549 more per woman when compared with usual care (95% CI £3175 252"
to £5922). Participants allocated to the FNP intervention accrued fewer QALYs than those for usual Care (-253"
0.007, 95% CI -0.042 to 0.027). Therefore the results of the complete case analysis indicate FNP was dominated 254"
by usual care. 255"
 256"
DISCUSSION 257"
 258"
This economic evaluation provides evidence that FNP is more costly than usual care and provides only a very 259"
small QALY gain. Similarly the analysis of uncertainty confirmed that it is unlikely that FNP represents an 260"
efficient intervention even if the cost was substantially reduced. The base case results indicate that the 261"
probability of FNP being cost-effective is 17%, with the results being robust to sensitivity analyses.  262"
There is evidence of positive results of the FNP intervention in the US, a context where mothers are not able to 263"
access many statutory supportive health and social services, and maternity community based services. In 264"
contrast, pregnant women in the UK can access a wide provision of maternal care including community care 265"
family doctors, midwives and public health nurses, and as we observed in our trial sites, specialist teenage 266"
pregnancy midwives as well. It is worth it to note that the differences between the US and UK health systems 267"
can explain the lack of clinical or quality-of-life benefits for those women who receive the FNP programme as a 268"
public service offered in the UK. The Building Blocks trial is the first UK-based trial of FNP, therefore this 269"
analysis represents the most up-to-date estimate of the cost-effectiveness of FNP when delivered in a universal, 270"
publicly funded, health care setting.  271"
There are two noteworthy limitations of this study. The first limitation relates to the level of missing data. 272"
Despite steps to minimise missing data (e.g. computer assisted telephone interviews), the number of EQ-5D 273"
questionnaires completed for each data collection wave decreased over time. This is a common problem in trial-274"
based economic evaluations that is amplified where there are frequent assessments, as in here. It is worth noting 275"
that the use of HES data helped to minimise considerably the problem of incomplete data thus enabling more 276"
accurate estimates of hospital costs. The second limitation relates to the duration of the BB trial. In our trial we 277"
are able to assess programme cost-effectiveness in the short-term only and we recognise that for preventative 278"
10"
"
programmes benefits may be expected to accrue over a longer time period and in domains of child development. 279"
Reported analyses of programme cost-effectiveness in the US have highlighted the advantage for high-risk 280"
families in particular over longer but variable periods of time. The Social Research Unit at Dartington, and 281"
Aldaba Limited conducted a cost-benefit analysis for FNP in the UK using a modelling approach which 282"
describes the longer-term savings by the FNP programme, indicating that key savings being related to higher 283"
earnings and higher attainment test scores [24] There have been some shortcomings identified with the 284"
economics analyses previously reported [25], for example some double counting of non-independent outcomes. 285"
In one meta-analytic review the cost savings for the programme were greatest for outcomes related to the mother 286"
(e.g. reduced crime, higher earnings, reduction in welfare) rather than the child [26]. Positive programme 287"
outcomes identified the trial include maternally reported child language development. This is of potential 288"
longer-term importance but requires further evaluation over the medium term to first verify with objective 289"
ratings and second to determine whether any short-term advantage is continued to improvements in later 290"
outcomes such as school readiness. These objectives are currently being assessed in a linked study. 291"
Besides it could be argued that we only look at QoL for the women and not the children. The EuroQol Group 292"
has developed a child-friendly EQ-5D version (EQ-5D-Y)[27], however the age of 8 is the lower age limit for 293"
which the instrument is valid hence the EQ-5D-Y was not applicable for the children in the BB trial. Regarding 294"
mothers, the EQ-5D-3L did detect differences in scores between stages of pregnancy (e.g. women reported more 295"
problems in pain/discomfort and mobility at late pregnancy than any other follow-up point); which shows that 296"
this instrument can capture small yet important changes which are important to reflect the impact of the 297"
intervention on health.  Similarly it could be debated that the QALY instrument lacks sensitivity for measuring 298"
the impact of FNP in health. Nonetheless within the UK the access to a new intervention has to be justified by 299"
the health gain it provides compared with usual care, where the added benefit is typically expressed in QALYs. 300"
In order to overcome the limitation of the QALY approach, this study was complemented with (i) a cost-301"
consequence analysis (Policy Research Programme Project April 2015); and (ii) a discrete choice experiment 302"
that examined the preferences of the general population for the outcomes of the trial. 303"
There are two main points that this study adds. From a research perspective, this study emphasises the need to 304"
conduct trials and to evaluate the effectiveness and cost-effectiveness of policy interventions before they are 305"
implemented. From a policy making perspective this study can contribute to everyday decision making 306"
regarding which services to offer to young pregnant women. Our findings provide strong evidence to suggest 307"
11"
"
that the delivery of FNP is not better for young mothers or their babies than comprehensive services in the short 308"
term, while costing more. There is currently evidence supporting other cost-effective public interventions among 309"
pregnant women aiming to address some of the primary outcomes of the BB trial, with a positive influence at a 310"
relatively low cost, and maybe cost saving (e.g. smoking cessation) (Ruger et al. 2008; Tappin et al. 2015).  311"
In England and Wales, there were 23 948 live births to women aged under 20 during 2015 (Statistics 2015)). If 312"
we assume that around 50% of these women were offered an FNP place then the annual cost saving in England 313"
from removing the FNP programme would be around £21 million. 314"
 315"
CONCLUSION 316"
The Building Blocks trial is the first UK-based trial of FNP. As discussed, the FNP intervention did not deliver 317"
significant benefits on any of the primary outcomes and only limited benefits on a small number of secondary 318"
outcomes where the risk of a chance finding is greater. Thus, taken together with the effectiveness findings, the 319"
results of this economic evaluation suggest that FNP does not represent a cost-effective intervention when 320"
adding FNP to existing services already offered to young pregnant women in England. However, it is important 321"
to note that these results are based on the two year trial only and cannot account for any longitudinal outcomes 322"
that may emerge at a later stage. Hence, at this time, we cannot recommend the continuation of FNP delivery 323"
and it may be the case that displacing the resources currently used in the FNP and investing in alternative 324"
interventions could potentially result in greater gains in child health, development and family economic stability 325"
for this population. 326"
 327"
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Table 1 Unit costs used for costing primary care and community services 453"
Item Unit  Cost Reference Notes 
GP  
 
 
 
Per Surgery consultation 
lasting 11.7 min 
 
Per out of surgery  (home 
visiting) lasting 23.4 min 
£45 
 
 
 
£114 
Unit Costs of Health 
and Social Care 2013 
Including direct care staff 
costs & qualifications 
GP Nurse  Per Surgery consultation 
lasting 15.5 minutes 
 
Per home visiting lasting 
23.4 min 
£13.4 
 
 
 
£27.3 
Unit Costs of Health 
and Social Care 2013 
Assume same duration 
than GP home visit 
Midwife  Antenatal visit 
(Community) 
 
Postnatal visit 
(Community) 
 
Home visit 
 
 
Midwife episode 
£51 
 
 
£68 
 
 
£70 
 
 
£65 
NHS reference costs 
2012/2013 
(NHS trusts and NHS 
foundation trusts) 
 
 
Unit Costs of Health 
and Social Care 2013 
Community Health 
Services – Health Visiting 
and Midwifery 
 
 
 
 
 
 
Total Outpatient 
attendances data 
Health visitor Per hour 
 
Per hour of home visiting 
£49 
 
£71 
Unit Costs of Health 
and Social Care 2010 
Assume same duration 
than GP home visits 
Counsellor Surgery consultation £58 Unit Costs of Health 
and Social Care 2013 
 
 
Mental health Per hour per team member £36 Unit Costs of Health 
and Social Care 2013 
Community mental health 
team for adults with 
mental health problems. 
Crisis Resolution team  Per hour per team member £37 Unit Costs of Health 
and Social Care 2013 
 
Support worker Per hour £22 Unit Costs of Health 
and Social Care 2013 
 
Social worker  Per hour  £79 Unit Costs of Health 
and Social Care 2013 
 
Physiotherapist Surgery session per hour 
 
Hospital session per hour 
£34 
 
£36 
Unit Costs of Health 
and Social Care 2013 
 
 
FNP Supervisor Nurse Clinic or phone visit 
per minute  
 
 
 
 
Home visit                  per 
minute 
£1.34 
 
 
 
 
 
£1.62 
Unit Costs of Health 
and Social Care 2013 
Qualified nursing, 
midwifery & health 
visiting staff by Agenda 
for change band 8a, NHS 
England.  
 
Ratio of direct time on: 
Home visits (1:0.45) 
Patient work (1:0.20) 
FNP Nurse Clinic or phone visit 
per minute 
 
 
 
 
Home visit                  per 
minute 
£1.17 
 
 
 
 
 
£1.41 
Unit Costs of Health 
and Social Care 2013 
Qualified nursing, 
midwifery & health 
visiting staff by Agenda 
for change band 7,           
NHS England.  
 
Home visits (1:0.45) 
Patient work (1:0.20) 
 
"454"
"455"
"456"
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Table 2 Complete cases 457"
" Complete Cases 
 FNP               
(n=808) 
Usual Care 
(n=810) 
EQ-5D Baseline 808 (100%) 807 (99%) 
EQ-5D 34-36 weeks 614 (76%) 616 (76%) 
EQ-5D 6 months 507 (63%) 469 (58%) 
EQ-5D 12 months 510 (63%) 480 (59%) 
EQ-5D 18 months 499 (62%) 465 (57%) 
EQ-5D 24 months 583 (72%) 537 (66%) 
EQ-5D all assessments 349 (41%) 265 (34%) 
GP records 480 (61%) 471 (60%) 
Hospital data (HES records) 808 (100%) 810 (100%) 
Complete-Case dataset ^ 217 (28%) 186 (24%) 
^ The complete dataset used for the base-case analysis comprised all mothers whose all six EQ-5D-3L 458"
assessments and all costs (GP records, health visitor/midwife visits and hospital attendances) were available.   459"
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Table 3 Mothers and babies average resource use per arm of the trial from baseline up to two years following child birth 
 
## FNP (n=782)  Usual Care (n=786)  
## n! Mean (SD) Min, Max Median  Missing  n Mean (SD) Min; Max Median  Missing  
GP surgery visits for mothers 471 9.55 (8.40) 0; 48 7 39.76% 480 8.49 (7.81) 0; 48 7 38.93% 
GP home visits for mothers 471 0.22 (0.84) 0; 9 0 39.76% 480 0.21 (0.76) 0; 8 0 38.93% 
Nurse surgery visits for mothers 471 2.14 (3.61) 0; 36 1 39.76% 480 2.22(3.01) 0; 20 1 38.93% 
Community Midwife visits 459 10.40 (5.34) 0;41 10 41.30% 422 10.68 (5.25) 0; 41 10 46.31% 
Community Health visitor visits 363 8.60 (13.74) 0; 68 0 53.58% 321 16.25 (12.15) 0;73 13 59.16% 
Community Counsellor visits 612 0.29 (1.23) 0;12 0 21.73% 614 0.32 (1.64) 0;20 0 21.88% 
Inpatient Length of Stay mothers 782 3.98 (6.35) 0; 99 3 0% 786 4.09  (6.39) 0;110 2 0% 
Day case admissions for mothers 782 3.53 (5.19) 0; 60 2 0% 786 3.57 (5.48) 0;77 2 0% 
Outpatient visits for mothers 782 8.61 (8.05) 0; 74 7 0% 786 8.55 (8.05) 0; 70 6.5 0% 
A&E attendances for mothers 782 4.54 (2.43) 0; 36 1 0% 786 1.58 (2.55) 0; 29 1 0% 
GP surgery visits for babies 471 8.17 (7.10) 0; 70 7 39.76% 480 7.60 (6.20) 0; 51 7 38.93% 
GP home visits for babies 471 0.29 (1.25) 0; 17 0 39.76% 480 0.29 (1.61) 0; 20 0 38.93% 
Nurse surgery visits for babies 471 0.88 (2.17) 0; 22 0 39.76% 480 0.90 (2.05) 0; 18 0 38.93% 
Inpatient length of stay for babies 724 2.82  (21.32) 445 ;0 0 0% 757 3.10  (25.29) 0; 466 0 0% 
Day case admissions for babies 724 1.74 (3.42) 0;34 0 0% 757 1.79 (3.31) 0; 32 0 0% 
Outpatient visits for babies 724 1.82 (5.29) 0;69 0 0% 757 2.08 (7.03) 0; 135 0 0% 
A&E attendances for babies 724 2.58 (3.24) 0; 30 2 0% 757 2.21 (2.53) 0; 15 1 0% 
FNP visits/encounters 709 39.28 (15.19) 1; 88 41 10% 10 0.45 (4.26) 0; 53 0 NA 
FNP phone calls  709 6.29 (5.34) 2; 31 4 10% 10 0 0 0 NA 
SD, standard deviation
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Table 4 Costs associated with all available cases: mean and standard deviation (in brackets). Costs discounted from year 2 at 3.5% according 
to ITT. Mean incremental costs and 95% CI estimated using OLS regression 
 
 
 
 
 
 
 
 
 
 
 
 
 
SD, standard deviation 
 
  Mean cost £ (SD) Difference (FNP - Usual 
Care) (95% CI)   FNP Usual Care  
GP surgery visits for mothers 429.95 (17.49) 382.35 (16.20) 47.60 (0.82; 94.37) 
GP home visits for mothers 25.82 (4.42) 24.92 (4.18) 0.89 (-11.96; 12.84) 
Nurse surgery visits for mothers 21.17 (1.69) 22.63 (1.41) -0.83 (-5.17; 3.50) 
Community Midwife visits  15.51 (332.38) 15.29 (314.19) -20.96 (-63.82; 21.89) 
Community Health visitor visits 135.67 (11.34) 217.78 (10.25) -82.10 (-112.42; -51.78) 
Community Counsellor visits 16.86 (71.56) 19.08 (94.79) -11.62; 7.20) 
Inpatient length of stay mothers 6354.57 (8460.72) 6661.17 (9679.04) -306.59 (-1193.20; 580.00) 
Day case admissions for mothers 775.22 (1041.62) 781.72 (1216.929) -6.50 (-116.98; 103.96) 
Outpatient visits for mothers 889.49 (903.30) 875.63 (918.99) 13.85 (-75.01; 102.71) 
A&E attendances for mothers 167.06 (277.82) 172.79 (289.34) -5.72 (-33.39; 21.93) 
GP surgery visits for babies 367.74 (14.92) 342.37 (12.80) 25.36 (-13.13; 63.86) 
GP home visits for babies 33.13 (6.64) 32.64 (8.38) 0.49 (-20.57; 21.56) 
Nurse surgery visits for babies 8.96 (1.03) 9.21 (0.95) -0.25 (-3.00; 2.50) 
Inpatient length of stay for babies  3773.35 (25939.83) 4882.99 (50019.88) -1109.634 (-5198.32979.6) 
Day case admissions for babies 142.02 (702.62) 145.17 (615.10) -3.15 (-70.38; 64.08) 
Outpatient visits for babies 290.96 (983.72) 272.92 (842.08) -18.03 (-111.56; 75.49) 
A&E attendances for babies 293.12 (370.60) 254.93 (298.36) 38.16 (3.94; 72.38) 
FNP visit/encounters 3845.32 (76.69) 47.27 (16.08) 3798.05 (3644.70; 3951.4) 
FNP phone calls 33.27 (2.84) 0 (0) 33.27 (27.70; 38.83) 
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Table 5 Summary of incremental analysis (ITT), cost-effectiveness results and uncertainty 
for the base case (highlighted) and sensitivity analyses 
Analysis Difference in 
costs
* 
Difference in 
QALYs*   
ICER for FNP 
intervention                                  
(£ per QALY) 
Probability FNP           
Cost-effective† 
£20 000/QALY 
Base case (MI) 1812  
(-2814; 5447) 
0.0030  
(-0.01; 0.02) 
Above              
£100,000 per QALY 
     17% 
Sensitivity i (CC) 4549 
(3175; 5922) 
-0.007 
(-0.042; 0.027) 
FNP                
dominated 
0% 
Sensitivity ii 1933  
(-2641;5654 ) 
0.005 
(-0.017; 0.027) 
Above              
£100,000 per QALY 
16% 
Sensitivity iii 2061 
(-1949; 6072) 
0.005  
(-0.014; 0.025) 
Above              
£100,000 per QALY 
17% 
Sensitivity iv 3272 
 (2288; 4295) 
0.004 
(-0.018; 0.025) 
Above              
£100,000 per QALY 
 0% 
Sensitivity v  360  
(-3680; 4352) 
0.005 
 (-0.013; 0.022) 
£73,924                   
per QALY 
45% 
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